Valuation: LAMY

Market Cap 1.97Cr 1.73Cr 1.6Cr 1.5Cr 2.8Cr 185.57Cr 2.85Cr 19Cr 7.44Cr 92Cr 7.39Cr 7.23Cr 318.49Cr P/E 2024 *
-
P/E 2025 30.3x
Enterprise Value 1.97Cr 1.73Cr 1.6Cr 1.5Cr 2.8Cr 185.57Cr 2.85Cr 19Cr 7.44Cr 92Cr 7.39Cr 7.23Cr 318.49Cr EV / Sales 2024 *
-
EV / Sales 2025 41,47,73,333x
Free-Float
90%
Yield 2024 *
-
Yield 2025 -
1 day+21.69%
Current month+16.83%
1 month-4.76%
3 months-10.57%
6 months+25.17%
Current year+39.97%
1 month 0.36
Extreme 0.36
0.44
Current year 0.26
Extreme 0.26
0.5
1 year 0.17
Extreme 0.1704
0.94
3 years 0.06
Extreme 0.06
16
5 years 0.06
Extreme 0.06
16
10 years 0.06
Extreme 0.06
16
Manager TitleAgeSince
Chief Executive Officer 61 14/11/2025
Director TitleAgeSince
Director/Board Member 61 14/11/2025
Change 5-day change 1-year change 3-year change Capi.($)
+21.69%0.00%+46.03% - 2.3Cr
+2.56%+7.12%-7.30%-0.26% 4.45TCr
+0.15%+7.61%+324.11%+565.24% 3.6TCr
+0.36%+5.50%+3.87%+54.57% 3.07TCr
+8.37%+8.76%+17.05%-13.29% 2.86TCr
+7.60%-1.09%+12.49%+20.82% 2.3TCr
-0.24%+2.97% - - 1.48TCr
+8.30%+12.19%+62.65%+129.55% 1.35TCr
+2.73%+7.16%+11.00%+18.45% 1.3TCr
+0.70%+2.97%+93.04%+93.04% 1.26TCr
Average +5.22%+4.15%+62.55%+108.52% 2.17TCr
Weighted average by Cap. +3.22%+4.99%+71.38%+125.31%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.02 1.08 0.02 0.11 0.04 0.53 0.04 0.04 1.86 0 0 0 0 0.01 0.35 0.01 0.04 0.01 0.17 0.01 0.01 0.61
Net income -25.81T -22.72T -20.96T -19.6T -36.72T -24.33L -37.41T -3L -97.55T -12L -96.89T -94.79T -41.75L 51.4T 45.25T 41.74T 39.03T 73.14T 48.44L 74.5T 5L 2L 23.9L 2L 2L 83.14L
Net Debt 56.07T 49.37T 45.53T 42.59T 79.79T 52.85L 81.28T 5L 2L 26.07L 2L 2L 90.71L -
Logo LAMY
LAMY is a clinical stage biotechnology company. The Company is engaged in developing and manufacturing mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The platform enables the custom production of exosomes with genetic functionality, capable of selectively targeting specific cells to address diseases with unmet medical needs. The engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer. Its proprietary manufacturing process utilizes plant-based materials to create exosomes used in various commercial applications, including dermatology and dentistry.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. LMMY Stock